Search

Displaying results 7161 - 7170 of 8517 in total
  1. Drug

    Cythioate

    go.drugbank.com/drugs/DB11392
    ExperimentalVet approved

    Cythioate is a member of the organothiophosphate compounds that is used as an insecticide and anthelmintic. It is mainly used in veterinary as a treatment for fleas.

  2. Drug

    V590

    go.drugbank.com/drugs/DB16437
    Experimental

    The V590 vaccine was developed on Merck’s recombinant vesicular stomatitis virus (rVSV) platform that was previously used to develop its Ebola Zaire virus vaccine, ERVEBO®[A226818, L30573, L30578].

  3. Drug

    IP501

    go.drugbank.com/drugs/DB06450
    Experimental

    The compound was developed by Indevus Pharmaceuticals.

  4. Drug

    XP12B

    go.drugbank.com/drugs/DB04928
    Investigational

    It was granted Fast Track status for this indication by the FDA in November 2004.

  5. Drug

    ALMB-0166

    go.drugbank.com/drugs/DB17937
    Investigational

    It was granted FDA orphan designation in November 2018.[L47067]

  6. Drug

    Rivipansel

    go.drugbank.com/drugs/DB12778
    Investigational

    Rivipansel has been used in trials studying the other, basic science, and treatment of Pain Crisis, Renal impairment, Anemia, Sickle Cell, Sickle Cell Disease, and Sickle Cell Disorders, among others.

  7. Drug

    KB3305

    go.drugbank.com/drugs/DB06349
    Experimental

    KB3305 is an investigational liver selective antagonist for the glucocorticoid receptor, developed by Karo Bio for the treatment of Type 2 Diabetes.

  8. Drug

    Technetium Tc-99m sestamibi

    go.drugbank.com/drugs/DB09161
    ApprovedInvestigational

    The mechanism by which sestamibi localizes to these tissues has not been established.

  9. Drug

    Galamustine

    go.drugbank.com/drugs/DB21062
    Experimental

    Galamustine has a monoisotopic molecular weight of 303.06 Da.

  10. Drug

    Naquotinib

    go.drugbank.com/drugs/DB12036
    Investigational

    Naquotinib has been used in trials studying the treatment of Solid Tumors, Non-small Cell Lung Cancer, Non-Small-Cell Lung Cancer (NSCLC), Epidermal Growth Factor Receptor Mutations, and Epidermal Growth